AMELUZ

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
AMELUZ
Generic name
AMINOLEVULINIC ACID HYDROCHLORIDE
Manufacturer
Biofrontera Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
650daa9f-aeec-49ce-95b9-5fa20b988afd
SPL ID
847bdc68-e91b-4fff-9d5c-68783babed23
Version
36
Effective date
2026-10-13
Source export date
2026-11-13
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:02:15
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5. WARNINGS AND PRECAUTIONS Hypersensitivity: Hypersensitivity reactions have been reported with the use of AMELUZ prior to photodynamic therapy (PDT). If a hypersensitivity reaction occurs, wash off AMELUZ and institute appropriate therapy ( 5.1 ). Transient Amnestic Episodes: Transient amnestic episodes have been reported with use of AMELUZ in combination with PDT. Advise patients to contact their healthcare provider if amnesia occurs after treatment ( 5.2 ). Risk of BF-RhodoLED or RhodoLED XL Lamp Induced Eye Injury: Patients and healthcare providers must wear protective eyewear before operating BF-RhodoLED or RhodoLED XL lamp ( 5.3 ). Ophthalmic Adverse Reactions: Avoid direct contact of AMELUZ with the eyes ( 5.4 ). Increased Photosensitivity: Protect treated lesions from sunlight exposure for 48 hours post treatment ( 5.5 ). Risk of Bleeding in Patients with Coagulation Disorders: Take special care to avoid bleeding during lesion preparation in patients with inherited or acquired coagulation disorders ( 5.6 ). Mucous Membrane Irritation: Avoid direct contact of AMELUZ with the mucous membranes ( 5.7 ). 5.1 Hypersensitivity Several cases of hypersensitivity were reported during postmarketing use of AMELUZ prior to PDT illumination [ see Adverse Reactions (6.2) ]. If hypersensitivity reactions occur, clean the area of skin where AMELUZ was applied and institute appropriate therapy. Inform patients and their caregivers that AMELUZ may cause hypersensitivity, potentially including severe cases (anaphylaxis). 5.2 Transient Amnestic Episodes Transient amnestic episodes have been reported during postmarketing use of AMELUZ in combination with PDT. Inform patients and their caregivers that AMELUZ in combination with PDT may cause transient amnestic episodes. Advise them to contact the healthcare provider if the patient develops amnesia after treatment. 5.3 Risk of BF-RhodoLED- or RhodoLED XL Lamp-Induced Eye Injury BF-RhodoLED or RhodoLED XL lamp may cause eye irritation, glare, vision blurred, visual impairment or injury. Before operating the lamp, personnel must refer to the user manual for specific warnings, cautions, and instructions. Eye exposure to the BF-RhodoLED or RhodoLED XL light must be prevented. Protective eye equipment must be used by patients, healthcare providers, and any person present during the illumination period. Avoid staring directly into the light source. 5.4 Ophthalmic Adverse Reactions Eyelid edema and dry eyes have occurred after PDT with AMELUZ. PDT with AMELUZ can cause ophthalmic adverse reactions. Avoid direct contact of AMELUZ with the eyes. Rinse eyes with water in case of accidental contact. 5.5 Increased Photosensitivity AMELUZ increases photosensitivity. Avoid sunlight, prolonged or intense light (e.g., tanning beds, sun lamps) on lesions and surrounding skin treated with AMELUZ for approximately 48 hours following treatment, whether exposed to illumination or not. Concomitant use of AMELUZ with other known photosensitizing drugs may increase the risk of phototoxic reaction to PDT [ see Drug Interactions (7) ]. 5.6 Risk of Bleeding in Patients with Coagulation Disorders AMELUZ has not been tested on patients with inherited or acquired coagulation disorders. Take special care to avoid bleeding during lesion preparation in such patients [ see Dosage and Administration (2.3) ]. Any bleeding must be stopped before application of AMELUZ. 5.7 Risk of Mucous Membrane Irritation AMELUZ can cause mucous membrane irritation. AMELUZ is intended for topical use only. Avoid direct contact of AMELUZ to the mucous membranes. Rinse with water in case of accidental contact.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6. ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: ​ Hypersensitivity [ see Warnings and Precautions (5.1) ]. Transient Amnestic Episodes [ see Warnings and Precautions (5.2) ] . Risk of BF-RhodoLED or RhodoLED XL Lamp Induced Eye Injury [see Warnings and Precautions (5.3) ] . Ophthalmic Adverse Reactions [see Warnings and Precautions (5.4) ]. Increased Photosensitivity [see Warnings and Precautions (5.5) ] . Most common adverse reactions (≥10%) were application site erythema, pain/burning, irritation, edema, pruritus, exfoliation, scab, induration, vesicles and paraesthesia ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Biofrontera Inc. at 1-844-829-7434 or FDA at 1-800-332-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Subjects with Mild-to-Moderate Actinic Keratosis The safety and efficacy of AMELUZ in combination with PDT using a narrow spectrum source was evaluated in three double-blind and placebo-controlled phase 3 trials (Trials 1, 2, and 3), enrolling a total of 299 subjects that were treated with narrow band light. Trial subjects were adults greater than or equal to 49 years of age, and the majority had Fitzpatrick skin type I, II, or III. No subjects had Fitzpatrick skin type V or VI. Approximately 86% of subjects were male, and all subjects were White [ see Clinical Studies (14.1) ]. For all three trials, the enrolled subjects had mild to moderate AKs (Olsen grade 1 and 2) with 4 to 8 lesions on the face and scalp. Overall, 212 AMELUZ-treated subjects (n=32, n=55, and n=125) and 87 subjects receiving placebo (n=16, n=32, n=39) were illuminated with BF-RhodoLED or similar narrow spectrum lamps. For these trials, the maximal dose was one tube of AMELUZ (2 g) and the size of the application area was up to 20 cm 2 . Local skin reactions at the application site were observed in about 99.5% of subjects treated with AMELUZ and narrow spectrum lamps. The most frequent adverse reactions during and after PDT were application site erythema, pain, burning, irritation, edema, pruritus, exfoliation, scab, induration, and vesicles. Most adverse reactions occurred during illumination or shortly afterwards, were generally of mild or moderate intensity, and lasted for 1 to 4 days in most cases; in some cases, however, they persisted for 1 to 2 weeks or even longer. Severe pain/burning occurred in up to 30% of subjects. In one case, the adverse reactions required interruption or discontinuation of the illumination. Table 1 presents the incidence of common (≥1%, <10%) and very common (≥10%) adverse reactions at the application site in Trials 1, 2, and 3. Table 1: Application Site Adverse Reactions Occurring at ≥1% of the AMELUZ Group and More Frequently than the Vehicle Group in Subjects with Mild-to-Moderate Actinic Keratosis (Trials 1, 2, and 3) Application Site Adverse Reaction AMELUZ n=212 Vehicle n=87 Erythema Pain/Burning Irritation Edema Pruritus Exfoliation Scab Induration Vesicles Paresthesia Hyperalgesia Reaction Discomfort Erosion Discharge Bleeding Pustules 195 (92%) 195 (92%) 153 (72%) 75 (35%) 72 (34%) 41 (19%) 41 (19%) 26 (12%) 25 (12%) 18 (9%) 13 (6%) 8 (4%) 7 (3%) 6 (3%) 4 (2%) 3 (1%) 3 (1%) 34 (39%) 26 (30%) 17 (20%) 3 (3%) 14 (16%) 4 (5%) 2 (2%) 0 (0%) 1 (1%) 2 (2%) 0 (0%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) In Trials 1, 2, and 3, common (≥1%, <10%) adverse reactions not at the application site in AMELUZ-treated subjects were headache, skin exfoliation, chills and eyelid edema. In Trials 1, 2, and 3, less common (≥0.1%, <1%) application site adverse reactions in AMELUZ-treated subjects were hemorrhage and swelling. Adverse reactions not at the application site were blister, feeling hot, pruritus, pyrexia, scab, nervousness, pain, petechiae, rash pustular, skin erosion and ulcer. In two open-label clinical trials to evaluate safety and tolerability, 116 subjects with actinic keratosis (AK) on the face and scalp were treated with three tubes (6 g) of AMELUZ applied to a 60 cm² area in combination with PDT. Most adverse reactions observed were consistent with those reported in trials using one tube (2 g) of AMELUZ on a 20 cm² area (Trials 1, 2, and 3) (see Table 1). Additional reactions which occurred in ≥1% of subjects when three tubes (6 g) of AMELUZ were applied to a 60 cm² area included dry eyes, photosensitivity, and application site discoloration, dryness, papules, and fissures. The frequencies of certain adverse reactions at the application site in these trials—exfoliation, itching, scabbing, and erosion—were more than 10% higher with the larger dose (three tubes, 6 g) and treatment area (60 cm²) compared to the frequencies observed in the trials for the smaller dose (one tube, 2 g) and area (20 cm²). Severe application site pain was reported in 41% of the subjects treated with three tubes (6 g) on a 60 cm² area. Most cases were reported during PDT illumination. A total of 15% of subjects discontinued illumination due to adverse reactions. Adverse Reactions in Subjects with Superficial Basal Cell Carcinoma The safety and efficacy of AMELUZ, in combination with PDT using the BF-RhodoLED lamp, was evaluated in a randomized controlled trial enrolling 187 adults (Trial 4) with superficial basal cell carcinoma (sBCC). Subjects received AMELUZ or vehicle followed by exposure to BF-RhodoLED red light. All subjects were White and the majority had Fitzpatrick skin type I, II, or III [ Clinical Studies (14.2) ]. Most of the enrolled subjects had one sBCC lesion. Approximately 48% of the lesions were located on the neck and/or trunk and 45% of the lesions were located on the extremities. All subjects treated with AMELUZ and BF-RhodoLED lamp developed at least one adverse reaction at the application site. The most common adverse reactions during and after AMELUZ treatment in combination with PDT were application site pain that may be severe, erythema, pruritus, edema, paraesthesia, scab, induration, and exfoliation. Table 2: Application Site Adverse Reactions Occurring at ≥1% of the AMELUZ Group and More Frequently than in the Vehicle Group in Subjects with sBCC (Trials 4) Application Site Adverse Reaction AMELUZ N = 145 Vehicle N = 42 Pain Erythema Pruritus Edema Paraesthesia Scab Induration Exfoliation Discoloration Vesicles Dysaesthesia Haemorrhage Dryness Hyperaesthesia Swelling 138 (95%) 100 (69%) 73 (50%) 42 (29%) 35 (24%) 30 (21%) 25 (17%) 25 (17%) 13 (9%) 12 (8%) 3 (2%) 3 (2%) 2 (1%) 2 (1%) 2 (1%) 12 (29%) 15 (36%) 11 (26%) 5 (12%) 5 (12%) 2 (5%) 3 (7%) 6 (14%) 1 (2%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Less common (≥0.1%, <1%) application site adverse reactions were atrophy, hypoesthesia, inflammation, ulcer and fatigue. Less common adverse reactions not at the application site were vision blurred, visual impairment, headache, and solar lentigo. AMELUZ in combination with PDT was also evaluated in another clinical trial (Trial 5) that included 110 adults with sBCC and safety findings were consistent with those observed in Trial 4. Sensitization Potential of Aminolevulinic Acid In a clinical trial designed to investigate the sensitization potential of aminolevulinic acid with 216 healthy subjects, 13 subjects (6%) developed allergic contact dermatitis after continuous exposure for 21 days with doses of aminolevulinic acid that were higher than the recommended dose for the treatment of AK or sBCC. 6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of AMELUZ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and subcutaneous tissue disorders: dermatitis allergic. Nervous system disorders: transient amnestic episodes. Eye disorders: eye irritation, diplopia, ocular hyperemia, photophobia. Immune System disorders: hypersensitivity.

adverse reactions table

<table ID="_RefTable1" width="874" cellpadding="0.5pt"> <caption>Table 1: Application Site Adverse Reactions Occurring at &#x2265;1% of the AMELUZ Group and More Frequently than the Vehicle Group in Subjects with Mild-to-Moderate Actinic Keratosis (Trials 1, 2, and 3)</caption> <colgroup> <col width="33%"/> <col width="33%"/> <col width="33%"/> </colgroup> <tbody> <tr> <td styleCode="Botrule Toprule" valign="top"> <paragraph>Application Site Adverse Reaction</paragraph> </td> <td styleCode="Botrule Toprule" valign="top"> <paragraph>AMELUZ n=212</paragraph> </td> <td styleCode="Botrule Toprule" valign="top"> <paragraph>Vehicle n=87</paragraph> </td> </tr> <tr> <td styleCode="Botrule" valign="top"> <paragraph>Erythema</paragraph> <paragraph>Pain/Burning</paragraph> <paragraph>Irritation</paragraph> <paragraph>Edema</paragraph> <paragraph>Pruritus</paragraph> <paragraph>Exfoliation</paragraph> <paragraph>Scab</paragraph> <paragraph>Induration</paragraph> <paragraph>Vesicles</paragraph> <paragraph>Paresthesia</paragraph> <paragraph>Hyperalgesia</paragraph> <paragraph>Reaction</paragraph> <paragraph>Discomfort</paragraph> <paragraph>Erosion</paragraph> <paragraph>Discharge</paragraph> <paragraph>Bleeding</paragraph> <paragraph>Pustules</paragraph> </td> <td styleCode="Botrule" valign="top"> <paragraph>195 (92%)</paragraph> <paragraph>195 (92%)</paragraph> <paragraph>153 (72%)</paragraph> <paragraph>75 (35%)</paragraph> <paragraph>72 (34%)</paragraph> <paragraph>41 (19%)</paragraph> <paragraph>41 (19%)</paragraph> <paragraph>26 (12%)</paragraph> <paragraph>25 (12%)</paragraph> <paragraph>18 (9%)</paragraph> <paragraph>13 (6%)</paragraph> <paragraph>8 (4%)</paragraph> <paragraph>7 (3%)</paragraph> <paragraph>6 (3%)</paragraph> <paragraph>4 (2%)</paragraph> <paragraph>3 (1%)</paragraph> <paragraph>3 (1%)</paragraph> </td> <td styleCode="Botrule" valign="top"> <paragraph>34 (39%)</paragraph> <paragraph>26 (30%)</paragraph> <paragraph>17 (20%)</paragraph> <paragraph>3 (3%)</paragraph> <paragraph>14 (16%)</paragraph> <paragraph>4 (5%)</paragraph> <paragraph>2 (2%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>1 (1%)</paragraph> <paragraph>2 (2%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>2 (2%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table ID="_RefTable1b" width="874" cellpadding="0.5pt"> <caption>Table 2: Application Site Adverse Reactions Occurring at &#x2265;1% of the AMELUZ Group and More Frequently than in the Vehicle Group in Subjects with sBCC (Trials 4)</caption> <colgroup> <col width="34%"/> <col width="33%"/> <col width="33%"/> </colgroup> <tbody> <tr> <td styleCode="Botrule Toprule" valign="top"> <paragraph>Application Site Adverse Reaction</paragraph> </td> <td styleCode="Botrule Toprule" valign="top"> <paragraph>AMELUZ N = 145</paragraph> </td> <td styleCode="Botrule Toprule" valign="top"> <paragraph>Vehicle N = 42</paragraph> </td> </tr> <tr> <td styleCode="Botrule" valign="top"> <paragraph>Pain</paragraph> <paragraph>Erythema</paragraph> <paragraph>Pruritus</paragraph> <paragraph>Edema</paragraph> <paragraph>Paraesthesia</paragraph> <paragraph>Scab</paragraph> <paragraph>Induration</paragraph> <paragraph>Exfoliation</paragraph> <paragraph>Discoloration</paragraph> <paragraph>Vesicles</paragraph> <paragraph>Dysaesthesia</paragraph> <paragraph>Haemorrhage</paragraph> <paragraph>Dryness</paragraph> <paragraph>Hyperaesthesia</paragraph> <paragraph>Swelling</paragraph> </td> <td styleCode="Botrule" valign="top"> <paragraph>138 (95%)</paragraph> <paragraph>100 (69%)</paragraph> <paragraph>73 (50%)</paragraph> <paragraph>42 (29%)</paragraph> <paragraph>35 (24%)</paragraph> <paragraph>30 (21%)</paragraph> <paragraph>25 (17%)</paragraph> <paragraph>25 (17%)</paragraph> <paragraph>13 (9%)</paragraph> <paragraph>12 (8%)</paragraph> <paragraph>3 (2%)</paragraph> <paragraph>3 (2%)</paragraph> <paragraph>2 (1%)</paragraph> <paragraph>2 (1%)</paragraph> <paragraph>2 (1%)</paragraph> </td> <td styleCode="Botrule" valign="top"> <paragraph>12 (29%)</paragraph> <paragraph>15 (36%)</paragraph> <paragraph>11 (26%)</paragraph> <paragraph>5 (12%)</paragraph> <paragraph>5 (12%)</paragraph> <paragraph>2 (5%)</paragraph> <paragraph>3 (7%)</paragraph> <paragraph>6 (14%)</paragraph> <paragraph>1 (2%)</paragraph> <paragraph>1 (2%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> <paragraph>0 (0%)</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.